- 04 June | MGP Strategy Series | GS Paper 4 (Ethics) with AIR 7 A.R. Rajah Mohaideen Click Here to register for the session →
- 04 June | GS Advance Program begins from 4th June 2026 | First 2 classes open to all Click Here to register for the event →
- 05 June | MGP Strategy Series | GS Paper 3 Strategy Session with AIR 406 Mannat Luthra Click Here to register for the session
- 06 June | Open Orientation on Essay Guidance Program (EGP 2026) Click Here to register →
- 07 June | Open Orientation for Current Affairs for Mains 2026 Click Here to register →
- 07 June | Sociology Optional Strategy Session with AIR 10 Ujjwal Priyank Click Here to register →
Source: The post is based on the article “World’s first intra-nasal vaccine for COVID developed by India has got approval from the Central Drugs Standard Control Organisation (CDSCO) for restricted use in emergency situations in the age group of 18 and above” published in PIB on 2nd December 2022.
What is the News?
World’s first intra-nasal vaccine for COVID named “iNCOVACC” has got approval from the Central Drugs Standard Control Organisation (CDSCO) for restricted use in emergency situations in the age group of 18 and above.
What is iNCOVAC Vaccine?
iNCOVAC (BBV154) is the World’s first intra-nasal vaccine.
Developed by: Bharat Biotech International Limited (BBIL)
The product development and Clinical trials of the vaccine were funded by the Department of biotechnology and BIRAC under the Mission COVID Suraksha Program.
Click here to read more about the vaccine
What are the other decisions taken by the Government?
Formation of Biotechnology Research and Innovation Council(BRIC)
BRIC will be an apex autonomous body of the Department of Biotechnology(DBT). It has been formed by subsuming 14 Autonomous Institutions of DBT.
Aim: To achieve centralized and unified governance to maximize the impact of biotech research.
